Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GSK) ) has provided an announcement.
On 26 February 2026, GSK announced that Japan’s Ministry of Health, Labour and Welfare accepted for review a new drug application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. This represents the first global regulatory filing for the potential first-in-class therapy in a country where nearly one million people live with the disease and chronic hepatitis B remains a leading cause of liver cancer.
The filing is backed by positive Phase III B-Well 1 and B-Well 2 trial data, in which bepirovirsen plus standard of care achieved statistically significant and clinically meaningful functional cure rates versus standard care alone, with an acceptable safety and tolerability profile. The drug, licensed from Ionis and already granted SENKU designation in Japan as well as other expedited statuses globally, could materially strengthen GSK’s position in hepatitis B if approved, opening a new market opportunity and potentially reshaping the standard of care in a large, underserved patient population.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company that develops and commercialises vaccines, specialty and general medicines, with a focus on infectious diseases and other high-burden conditions. The company aims to combine science, technology and talent to deliver treatments that modify disease progression and address significant unmet medical needs worldwide.
Average Trading Volume: 4,919,155
Technical Sentiment Signal: Buy
Current Market Cap: $120.5B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.